PMID- 23376106
OWN - NLM
STAT- MEDLINE
DCOM- 20130828
LR  - 20181202
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 15
IP  - 4
DP  - 2013 Apr
TI  - Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue 
      for the treatment of spinal cord injury.
PG  - 434-48
LID - S1465-3249(12)00064-3 [pii]
LID - 10.1016/j.jcyt.2012.11.015 [doi]
AB  - BACKGROUND AIMS: Bone marrow and subcutaneous adipose tissue are both considered 
      prospective sources of mesenchymal stromal cells (MSCs), which can be used in 
      cell therapy for spinal cord injury (SCI). The present study investigated whether 
      human adipose tissue-derived mesenchymal stromal cells (hADSCs) transplanted into 
      a rat model of SCI would lead to similar or improved neurologic effects compared 
      with human bone marrow-derived mesenchymal stromal cells (hBMSCs). METHODS: 
      hADSCs and hBMSCs were isolated from five adult donors. These MSCs were 
      characterized using flow cytometry, immunocytochemistry, real-time polymerase 
      chain reaction and enzyme-linked immunosorbent assay. Immediately after SCI, 2 x 
      10(5) hBMSCs or hADSCs were injected into the injured spinal cord. Locomotor 
      function, cell survival and differentiation, spinal cord tissue morphology and 
      brain-derived neurotrophic factor (BDNF) expression were compared between groups. 
      RESULTS: hADSCs and hBMSCs showed similar surface protein expression, and hADSCs 
      showed higher proliferative activity with higher expression of vascular 
      endothelial cell growth factor, hepatocyte growth factor and BDNF than hBMSCs. 
      After transplant, both hADSCs and hBMSCs migrated within the injured spinal cord 
      without differentiating into glial or neuronal elements. Administration of hADSCs 
      was associated with marked changes in the SCI environment, with significant 
      increases in BDNF levels. This was simultaneously associated with increased 
      angiogenesis, preserved axons, decreased numbers of ED1-positive macrophages and 
      reduced lesion cavity formation. These changes were accompanied by improved 
      functional recovery. CONCLUSIONS: The present results suggest that hADSCs would 
      be more appropriate for transplant to treat SCI than hBMSCs.
CI  - Copyright (c) 2013 International Society for Cellular Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Zhou, Zhilai
AU  - Zhou Z
AD  - Department of Orthopedics, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Chen, Yinhai
AU  - Chen Y
FAU - Zhang, Hui
AU  - Zhang H
FAU - Min, Shaoxiong
AU  - Min S
FAU - Yu, Bo
AU  - Yu B
FAU - He, Bing
AU  - He B
FAU - Jin, Anmin
AU  - Jin A
LA  - eng
PT  - Journal Article
DEP - 20130201
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Ectodysplasins)
SB  - IM
MH  - Adipose Tissue/*cytology
MH  - Animals
MH  - Bone Marrow Cells/*cytology
MH  - Brain-Derived Neurotrophic Factor/biosynthesis/metabolism
MH  - Cell Differentiation
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Ectodysplasins/biosynthesis
MH  - Female
MH  - Humans
MH  - Macrophages/metabolism
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*cytology
MH  - Middle Aged
MH  - Neovascularization, Physiologic
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spinal Cord/metabolism
MH  - Spinal Cord Injuries/*therapy
EDAT- 2013/02/05 06:00
MHDA- 2013/08/29 06:00
CRDT- 2013/02/05 06:00
PHST- 2012/04/19 00:00 [received]
PHST- 2012/10/25 00:00 [revised]
PHST- 2012/11/30 00:00 [accepted]
PHST- 2013/02/05 06:00 [entrez]
PHST- 2013/02/05 06:00 [pubmed]
PHST- 2013/08/29 06:00 [medline]
AID - S1465-3249(12)00064-3 [pii]
AID - 10.1016/j.jcyt.2012.11.015 [doi]
PST - ppublish
SO  - Cytotherapy. 2013 Apr;15(4):434-48. doi: 10.1016/j.jcyt.2012.11.015. Epub 2013 
      Feb 1.